Trevi Therapeutics (TRVI) Accumulated Depreciation (2018 - 2025)

Trevi Therapeutics' Accumulated Depreciation history runs 8 years deep, the most recent figure standing at $359000.0 for Q4 2025.

• In Q4 2025, Accumulated Depreciation rose 57.46% year-over-year to $359000.0; the TTM figure through Dec 2025 stood at $359000.0 (up 57.46% YoY), while the FY2025 annual figure was $359000.0, up 57.46% from the prior year.
• Accumulated Depreciation for Q4 2025 stood at $359000.0, up from $228000.0 in the prior quarter.
• The five-year high for Accumulated Depreciation was $359000.0 in Q4 2025, with the low at $134000.0 in Q4 2023.
• The 5-year median for Accumulated Depreciation is $225000.0 (2022), against an average of $225600.0.
• The sharpest annual moves came in 2023 and 2024: Accumulated Depreciation sank 40.44% in 2023, then jumped 70.15% in 2024.
• Trevi Therapeutics' Accumulated Depreciation stood at $182000.0 in 2021, then grew by 23.63% to $225000.0 in 2022, then tumbled by 40.44% to $134000.0 in 2023, then surged by 70.15% to $228000.0 in 2024, then soared by 57.46% to $359000.0 in 2025.
• Business Quant data shows TRVI's Accumulated Depreciation at $359000.0 in Q4 2025, $228000.0 in Q4 2024, and $134000.0 in Q4 2023.